Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
Date:8/27/2008

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview on Thursday, September 4 at 4:00pm Eastern Time (1:00pm Pacific Time) during the 2008 NewsMakers In the Biotech Industry Conference at the Millennium Broadway Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence

Pharmaceuticals, Inc.

Contacts:

William R. LaRue Anna Gral
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... According to new market research report "Cloud Professional ... & Support), by Service Model (SaaS, PaaS, IaaS), ... & Community)) - Global Forecast to 2019", published ... Services Market into various sub-segments with an in-depth ... the drivers and restraints for this market with ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014  aTyr ... today that rare disease expert John C. McKew ... Dr. McKew brings more than two decades of expertise ... National Institutes of Health, Wyeth Research and Genetics Institute, ... lead aTyr,s efforts to expand and translate its novel ...
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
Breaking Biology Technology:Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... at ProHEALTH Facility by End of First Quarter, ... NBS ),which is pioneering the pre-disease collection, processing and ... today announced,receipt of a provisional license for comprehensive tissue ... the New York State,Department of Health for the ProHEALTH ...
... of the ... Agency, MOUNTAINSIDE, N.J., Feb. 5 L&M Healthcare,Communications ... of Vice President, Scientific Services. Dr. Karasinski joins L&M,after ... Information,department of Schwarz Pharma and previously with the Medical ...
... Feb. 5 GeneGo, Inc., the leading,systems biology ... their,licensing agreement with GeneGo and have added additional ... and clinical studies,with global access to MetaCore, MapEditor ... analysis of biological OMICs data,featuring a comprehensive collection ...
Cached Biology Technology:NeoStem Announces NY State License for Adult Stem Cell Collection 2NeoStem Announces NY State License for Adult Stem Cell Collection 3L&M Healthcare Communications, LLC, Hires Scott Karasinski, PharmD 2GSK Extends GeneGo License and Adds New Products 2
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... that babies that are breastfed for longer than six months ... are based on data from the ground-breaking Raine Study at ... the growth and development of more than 2500 West Australian ... Wendy Oddy said there was growing evidence that bioactive factors ...
... Thanks to the many blood-safety interventions introduced since ... has become exceedingly small. , In the September ... Medicine, Dr. Morris Blajchman, professor of Medicine at ... (Hamilton Centre), with co-author Dr. Eleftherios Vamvakas of ...
... of Georgia professor Richard Hussey has spent 20 years ... a microscope. His discovery is vastly bigger. Hussey and ... the damage caused by one of the world's most ... the most economically important group of plant-parasitic nematodes worldwide, ...
Cached Biology News:Blood transfusion-transmitted infections: A global perspective 2UGA scientists engineer root-knot nematode resistance 2
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
... Baculovirus Transfer Vector is a derivative of the ... for blue fluorescent protein (BFP), followed by a ... genes are expressed as BFP-6xHis fusion proteins when ... (EcoR I, Stu I, Sac I, Not I, ...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Biology Products: